The NUDT22 antibody is a research tool designed to detect and study the Nudix hydrolase 22 (NUDT22) protein, a member of the Nudix family of enzymes involved in nucleotide metabolism. NUDT22. also known as DIPP7. is implicated in hydrolyzing modified nucleoside diphosphates, including oxidized or damaged nucleotides, to maintain genomic stability and regulate cellular nucleotide pools. Its enzymatic activity suggests roles in DNA repair, redox homeostasis, and potentially in cancer biology, though its precise physiological functions remain under investigation.
Antibodies targeting NUDT22 are typically developed using recombinant protein fragments or synthetic peptides to ensure specificity. These antibodies enable researchers to analyze NUDT22 expression patterns in tissues or cell lines via techniques like Western blotting, immunohistochemistry, or immunofluorescence. They are critical for exploring NUDT22's involvement in diseases, such as its reported dysregulation in certain cancers or neurodegenerative disorders. Validation often includes knockout cell controls or siRNA knockdown to confirm target specificity.
Current studies focus on linking NUDT22’s enzymatic activity to cellular stress responses, making its antibody a valuable reagent for uncovering its biological significance and potential therapeutic applications. Commercial availability varies, with some antibodies optimized for specific applications, driving ongoing research into its molecular mechanisms and disease associations.